Zacks Investment Research upgraded shares of OxySure Systems, Inc. (OXYS) from N/A to OUTPERFORM on January 14, 2013, with a target price of $1.75.
We are initiating coverage of OxySure Systems, Inc. with an Outperform rating and price target of $1.75 per share. We believe that the company's Model 615 Emergency Oxygen System is a potential breakthrough product for the delivery of medical oxygen in a medical emergency required supplemental oxygen, such as a cardiac arrest or acute asthma attack. We see several distinctive advantages of the Model 615 over portal oxygen cylinders, which are typically not designed for emergency use. We think that OxySure can turn cash flow positive in 2016, and generate over $10 million in operating cash flow in 2018. We built a 10-year discounted cash flow model that pegs fair-valuation between $1.50 and $2.00 per share. Thus, we are initiating coverage today with a target of $1.75 per share.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on OxySure Systems, Inc. (OXYS),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment